Form 4: Aquestive Therapeutics Director Douglas K. Bratton Reports Share Transactions

Director Douglas K. Bratton reported a transaction involving 40,000 shares of Aquestive Therapeutics common stock, along with details of his indirect holdings through various entities.

Summary

• Douglas K. Bratton, a director at Aquestive Therapeutics, reported a transaction on December 2, 2024, involving 40,000 shares of common stock.
• These shares were acquired through an in-kind pro rata distribution for no consideration, without a change in pecuniary interest.
• Bratton also has indirect beneficial ownership of a significant number of shares through various entities including MonoLine Partners, L.P., MonoLine Rx, L.P., MonoLine Rx II, L.P., MonoLine Rx III, L.P., and MonoSol Rx Genpar, L.P.
• Bratton Capital Management, L.P. is the general partner of the Monoline Entities, and Bratton Capital, Inc. is the general partner of Bratton Capital Management.
• Douglas K. Bratton is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities and Monosol.
• The report also details indirect holdings by Bratton's spouse, acquired through similar in-kind distributions.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing share transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of share transactions by a company director, which is a standard practice in publicly traded companies. It provides transparency into the ownership structure and insider activity.

Comparison to Industry Standards

• The reporting of share transactions by directors is a common practice across all publicly listed companies, as mandated by the SEC.
• Similar filings are made by directors and officers of companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) when they engage in transactions involving their company's stock.
• The level of detail provided in this Form 4 is consistent with the requirements and standards set by the SEC for such disclosures.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the share ownership of a key director.
• The information is relevant for investors tracking insider transactions.

Key Dates

Keywords

Aquestive Therapeutics, Douglas K. Bratton, Beneficial Ownership, SEC Form 4, Share Transaction, Director Holdings, Monoline Partners, Monosol